anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to cataplasmata, namely a swelling pain eliminating plaster, which is used for treating bone fracture, bone diseases, arthritis, and surgical sores and ulcers, and is prepared from pure traditional Chinese medicines. Nineteen traditional Chinese medicine raw materials such as dandelion, radix puerariae, rhizoma drynariae, Cortex Ilicis Rotundae, Japan Yam Rhizome, glossy ganoderma are used for prescription; the traditional Chinese medicine raw materials are crushed first, are extracted through methods such as water extraction and alcohol extraction respectively, and are condensed into a thick ointment shape; and an excipient is added to be prepared into the latest cataplasm type traditional Chinese medicine ointment. Through the clinical observation, the plaster has functions of strengthening body resistance such as promoting blood circulation and removing blood stasis, dredging the channels, reducing swelling and relieving pain, removing blood stasis and toxic substances, and reuniting bones to human bodies, ensures that the qi and blood of the human bodies operate normally, makes the pain disappear due to the fact that no pain exists when the human bodies are smooth, removes blood stasis and toxic substances, and prevents the change caused by persistent injuries. Therefore, during the treatment of traumatic fracture, the plaster relieves pain, promotes the formation of poromas in times, can greatly shorten the healing period of bone fracture, and can prevent various disadvantages caused by stopping the natural healing of bone fracture patients. The plaster can improve bone substance, eliminate the necrosis, and has functions of removing blood stasis and toxic substances, so the plaster has healing effect on diseases such as osteomyelitis, bone necrosis, bone tuberculosis and late cancer pain. The plaster has remarkable treatment effect on various osteoarthropathies such as rheumatoid diseases and bone regeneration.
This study will develop and implement a mobile technology-delivered psychosocial intervention for opioid-dependent adults in methadone maintenance treatment (MMT). This novel therapeutic system promises to be cost-effective and to enable the provision of flexible, on-demand therapeutic support outside of the formal treatment setting. The specific aims of this investigation are as follows: Aim 1: The investigators will develop a novel, interactive, evidence-based psychosocial intervention delivered via mobile phones, designed to promote skills acquisition and reduce illicit drug use. Specifically, our Mobile Therapeutic System (MTS) will offer key elements of a psychosocial intervention for substance use disorders of known efficacy (the Community Reinforcement Approach). Participants will be provided with unlimited daily prompts to encourage use of the program and will be able to access the application at any time and as much as they choose, within their natural environments. Our iterative development process will include input from focus groups with clients in methadone treatment (n=24), input from experts in the field, and feedback testing of a beta-version of the mobile phone-based program with clients in methadone treatment (n=30). Aim 2: The investigators will evaluate the efficacy of this mobile tool with participants entering MMT during the first three months of their treatment (n=219). The investigators will evaluate the relative preliminary efficacy of (1) standard treatment, (2) standard treatment plus MTS and (3) a mobile-based control condition on the primary outcomes of retention and opioid use (via urine toxicology) and secondary outcomes of other substance use (via urine toxicology and self-report), readiness to change drug use behavior, coping skills, opioid craving, HIV risk behavior, and psychosocial functioning during the 3-month intervention phase. Durability of effects will be examined at 1 and 3 month follow-ups. Aim 3: The investigators will perform an economic analysis of MTS in community-based MMT. The investigators will estimate the incremental costs and the incremental cost-effectiveness ratio (ICER) of MTS relative to standard care and the mobile control group. The primary ICER will be the incremental costs per increased abstinence time (the clinical measure of effectiveness) and the secondary ICER will be incremental costs per increased quality adjusted life year (QALY) (the economic measure of effectiveness). Cost data will be vital to future translational projects to disseminate effective mobile interventions in community systems. If results are promising, this novel therapeutic tool may have a tremendous impact on improving access to and effectiveness of substance abuse treatment in a variety of other populations (and could also be adapted for an array of other behavioral health applications), while significantly limiting costs.
PURPOSE:To prepare a diuretic useful for the prevention and remedy, etc. of edema and ascites caused by nephropathy, by using 1-kestose, nystose and 1F fructofuranosyl nystose as active components. CONSTITUTION:The objective diuretic contains the compound of formula composed of sucrose (GF) consisting of glucose (G) bonded with fructose (F) and 1- 3 molecules of fructose bonded to the fructose fragment of said sucrose through beta2-1 bond, i.e. 1-kestose (n=2), nystose (n=3) and 1F fructofranosyl nystose (n= 4), as active components. The present fructo-oligosaccharide diuretic exhibits strong diuretic effect by a mechanism different from that of the conventional diuretic, and ameliorates the edema caused by various diseases such as cardiopathy, nephropathy such as acute hepatitis, renal insufficiency, nephrosis, etc. The compound is also expected to prevent the hepatic coma and uremia.
The present invention relates to a mask pack sheet, in particular, to a mask pack sheet composed of a non-woven fiber assembly including a lyocell fiber with fineness of 1.0 to 1.4 denier. The mask pack sheet of the present invention is composed of a non-woven fiber assembly including a lyocell fiber such that the sheet has enhanced stretchability not to be separated from skin of a user even when the user wears the sheet for a long time, thereby having increased adhesiveness to the skin. Absorption of essence or moisture and transparency after treatment of the essence or moisture can be improved as well. In addition, the mask pack sheet can be used as a support sheet for a cosmetic mask pack to give enhanced adhesiveness to the skin and wearability and excellent absorption such that nutrients can be effectively supplied to the skin. Furthermore, as moisturizing and transparency is improved, the mask pack sheet closely attached to the face of the user seems transparent rather than white such that the mask pack sheet looks similar to a face color of the user. Accordingly, difference from a real face is reduced and the appearance of the user will look aesthetic after wearing the mask pack sheet.
Once enrolled, participants will be administrated Baozhu Keli and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
PURPOSE:To obtain the titled composition, containing a nonionic surfactant having an HLB within a specific range and water-soluble high polymer compound crosslinked with a polyvalent metal, capable of homogeneously gelatinizing at an optional crosslinking rate and optionally selecting moisture content and having improved shape holding property as well as tackiness. CONSTITUTION:A composition obtained by emulsifying an aqueous solution of a polyvalent metal salt with a nonionic surfactant, e.g. polyoxyethylene alkyl ether compound or glyceryl alkyl ether compound, having <=8 HLB, adding a solution of powder of a water-soluble high polymer compound to the resultant emulsion, homogeneously blending both and destroying the emulsion system to give the aimed application agent composition. The ingredients are preferably used in the following amounts based on the total composition. 1-30wt% water- soluble high polymer and 0.01-5wt%, particularly 0.5-3wt% surfactant. The polyvalent metal salt is used in an amount of 0.01-5 equivalents, particularly 0.1-2 equivalents based on 1 equivalent crosslinkable part of the high polymer compound.
Interleukin-6 (IL-6) has been long considered a key player in cancer cachexia. It is believed that sustained elevation of IL-6 production during cancer progression causes brain dysfunctions, which ultimately result in cachexia. However, how peripheral IL-6 influences the brain remains poorly understood. Here we show that neurons in the area postrema (AP), a circumventricular structure in the hindbrain, is a critical mediator of IL-6 function in cancer cachexia in male mice. We find that circulating IL-6 can rapidly enter the AP and activate neurons in the AP and its associated network. Peripheral tumor, known to increase circulating IL-6, leads to elevated IL-6 in the AP, and causes potentiated excitatory synaptic transmission onto AP neurons and AP network hyperactivity. Remarkably, neutralization of IL-6 in the brain of tumor-bearing mice with an anti-IL-6 antibody attenuates cachexia and the hyperactivity in the AP network, and markedly prolongs lifespan. Furthermore, suppression of Il6ra, the gene encoding IL-6 receptor, specifically in AP neurons with CRISPR/dCas9 interference achieves similar effects. Silencing Gfral-expressing AP neurons also attenuates cancer cachectic phenotypes and AP network hyperactivity. Our study identifies a central mechanism underlying the function of peripheral IL-6, which may serve as a target for treating cancer cachexia.
<P>PROBLEM TO BE SOLVED: To provide a sustained release pharmaceutical preparation specifically deliverable to the large intestine and sustainedly releasing an effective amount of a medicinally effective ingredient.  <P>SOLUTION: The sustained release pharmaceutical preparation comprises a high-temperature swelling gel-like polymer (A) and a drug (b) absorbed for acting in the large intestine. The gel-like polymer is preferably swelled at a temperature in the large intestine. The surfaces of the gel-like polymer (A) and the therapeutic agent (b) for the diseases in the large intestine are preferably coated with an enteric film. The gel-like polymer (A) is preferably a polymer composite having an interpenetrating network structure of a cross-linkable polymer containing (a-1) an acrylamide or a methacrylamide unit (i) and an N-alkyl-substituted (meth)acrylamide unit (ii) as essential constituent units with (a-2) a cross-linkable polymer containing (a-2) an acrylic or a methacrylic acid unit (i) and the N-alkyl-substituted (meth)acrylamide unit (ii) as essential constituent units.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Participants assigned to the VIDEO arm will receive one brief Diabetes Self-Management Education and Support (DSMES) video per week for 24 weeks. The videos will be delivered via text message.
The present invention provides the use of CYR61 protein and inhibitors thereof for preparing medicine for treating rheumatic diseases, wherein the inhibitors are selected from anti-CYR61 antibody or interfering RNA of CYR61 gene. The technical scheme of present invention are: application of CUR61 protein in preparing medicine for treating rheumatic diseases; the rheumatic disease displayed here is rheumatoid arthritis (RA). The advantages of present invention are: discovering the usage of CYR61 as medicine; developing a new field for CYR61 application. Present invention displays the results that CYR61 has ability to enhance proliferation of fibroblast-like synoviocyte (FLS) derived from RA patients, which further results in damage of joint cartilage and bone in RA patients. CYR61 can inhibit FLS apoptosis while increases proliferation of FLS. Another way is that CYR61 induces expression of metal proteases up-regulation which further leads to damage of joint cartilage and bone. The invention also shows using some inhibitors, such as anti-CYR61 antibody or interfering RNA of CYR61 gene can block pathogenesis of CYR61. These results supply experimental evidences for screening therapeutic targets for biomedical and small molecules treatment in the future. The invention has the value for clinical application.
Systems and methods of quickly recognizing or differentiating many objects are presented. Contemplated systems include an object model database storing recognition models associated with known modeled objects. The object identifiers can be indexed in the object model database based on recognition features derived from key frames of the modeled object. Such objects are recognized by a recognition engine at a later time. The recognition engine can construct a recognition strategy based on a current context where the recognition strategy includes rules for executing one or more recognition algorithms on a digital representation of a scene. The recognition engine can recognize an object from the object model database, and then attempt to identify key frame bundles that are contextually relevant, which can then be used to track the object or to query a content database for content information.
A compsn. which modifies intestinal flora contains yeast, a lactobacillus and colibacillus type microorganisms and also vitamin B12 and gp. B vitamins; the microorganisms being lyophilised in order to preserve the medicament. The compsns. may be used to treat colitis, enterocolitis, acute and chronic diarrhoea, constipation, and digestive disorders. The microorganisms may be living or dead, although the colibacillus is pref. dead since the pathogenic props are very variable. The yeast is pref. Saccharomyces cerevisiae although other non-pathogenic, naturally antibiotic-resistant yeast such as S. boulardii, S. fragilis, S lactis and Torula utilis may be used, pref. at 20 x 109 yeast cells g-1 and the lactobacillus is pref. L. acidophilus opt. with Streptococcus lactis.
PROBLEM TO BE SOLVED: To prepare a preventing agent for poliosis capable of basically converting gray hair into black hair without hair coloring by using an extract obtained by immersing Sesamum indicum L. and two other plants in an alcoholic extract solution of a specific plant having actions such as blood purification. SOLUTION: This preventing agent for poliosis is obtained by blending an alcoholic extract from Impatience balsamina L. with extract solutions obtained by separately immersing Sesamum indicum L., Swertia japonicum Makino and Hibiscus syriacus L. in a mixture solution of the alcoholic extract solution of the Impatience balsamina L. with an aqueous solution containing ethyl alcohol at >=10 deg. alcoholic strength.  The resultant preventing agent for the poliosis is preferably prepared by especially mixing 2 pts.wt. extract solution of the Impatience balsamina L. with 2 pts.wt. aqueous solution containing ethyl alcohol at >=10 deg. alcoholic strength, 4 pts.wt. extract solution from the Sesamum indicum L., 1 pt.wt. extract solution from the Swertia japonicum Makino and 1 pt.wt. extract solution from Hibiscus syriacus L., allowing the resultant mixture solution to stand for 7-10 days and aging the mixture solution. The extract solution from the Impatience balsamina L. is obtained by immersing 20-50 pts.wt. whole herb of the Impatience balsamina L. in 100 pts.wt. aqueous solution containing the ethyl alcohol at >=10 deg. alcoholic strength (e.g. a white liquor) and separating the residue.
TMC278 is being investigated for treatment of HIV infection. Raltegravir is a commercially available HIV drug. The results of this study will provide dosing recommendations for coadministration of TMC278 and raltegravir in HIV-infected patients. This is a Phase I, open-label (both participant and investigator know the name of the medication given at a certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 24 healthy volunteers to investigate the pharmacokinetic interaction between TMC278 and raltegravir, at steady state. The study will consist of 3 phases: a screening phase, an open-label treatment phase consisting of 2 treatment periods, and end-of-study or withdrawal assessments. The duration of participation in the study for an individual participant will be up to 3 months (including screening). All participants will be randomly assigned to 1 of 2 possible treatment sequences and receive the following 2 treatments (Trt-s): TMC278 25 mg, once daily, alone for 11 days (TrtA), and raltegravir 400 mg, twice daily, alone for 4 days immediately followed by coadministration of the same raltegravir dose plus TMC278 25 mg, once daily, for 11 days (TrtB+C). There will be a washout period (a period where no study drug will be taken in view of having all the medication eliminated from the body before starting a new treatment) of at least 14 days between last intake of study medication in one session and first intake of study medication in the subsequent session. Pharmacokinetic profiles of both compounds will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and in follow-up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, before medication intake in TrtA on Days 1, 11, and 12 (Day 12 is without ECG), in TrtB+C on Days 1, 4, 5, 15, and 16 (Day 16 is without ECG) and at the 2 follow-up visits (but without ECG) at 1 week and 4 weeks after last dose of study medication in the last session. A physical examination will be performed at screening, on Days 10 and 12 of TrtA, on Days 3, 14, and 16 of TrtB+C, and at both follow-up visits. Healthy volunteers will stay overnight in the study center for 3 nights in TrtA and for 5 nights in TrtB+C. Each volunteer will receive in a randomized order 2 treatments, minimum 14 days apart from each other. TrtA is TMC278 25 mg, once daily, for 11 days. TrtB+C is raltegravir 400 mg, twice daily, alone for first 4 days (TrtB) followed by coadministration of 400 mg raltegravir, twice daily, and TMC278 25 mg, once daily, on Days 5 to 15 (TrtC).
Bone metastases are frequently one of the first signs of disseminated disease in cancer patients. Skeletal complications due to metastatic disease include (severe) bone pain, spinal cord compromise, pathological fractures, and hypercalcemia.

Zoledronic acid is a member of a class of compounds known as bisphosphonates. Bisphosphonates are effective inhibitors of osteoclastic bone resorption and have demonstrated therapeutic efficacy in the treatments of hypercalcemia of malignancy, lytic bone disease associated with multiple myeloma, and mixed lytic and blastic bone metastases associated with breast cancer. The precise mechanism by which bisphosphonates inhibit osteoclast function is not fully understood, but may include a direct toxic effect on mature osteoclasts, an inhibition of osteoclast production from precursor cells, and an impairment of osteoclast chemotaxis to sites of active bone resorption. Osteoclasts are specialized bone cells which erode mineralized bone by secreting acids and lysosomal enzymes. In normal bone remodeling, osteoclastic bone resorption is coupled to and is in equilibrium with osteoblastic bone formation. The lytic bone destruction associated with malignant bone metastases develops because tumor cells synthesize and release soluble factors that stimulate osteoclasts to resorb bone. The osteoclastic activating factors released by tumor cells include parathyroid hormone-related peptide (PTHrP), growth factors, and cytokines. The malignant activation of osteoclasts results in a disruption of normal bone remodeling wherein the equilibrium between bone resorption and bone formation is shifted toward increased bone resorption. This relative increase in osteoclastic bone resorption results in a net loss of bone. Thus, the predominant role of the osteoclast in the pathogenesis of bone destruction and the inhibitory effects of bisphosphonates on osteoclast function have formed the rationale for the use of bisphosphonates in the treatment of osteolytic bone metastases. The common role, regardless of tumor type, of the osteoclast as the mediator of bone destruction in metastatic skeletal disease is indicated by the inhibitory effects of bisphosphonates on tumor-induced osteolysis in animal models utilizing various malignant cell lines and the effectiveness of bisphosphonates in the therapy of tumor-induced hypercalcemia arising from any type of cancer. Moreover, recent studies have specifically shown that therapy with the bisphosphonate pamidronate (Aredia) combined with antineoplastic therapy significantly reduces the proportion of patients having skeletal complications due to the lytic bone disease associated with multiple myeloma and breast cancer compared to antineoplastic therapy alone.
A device includes a material and a silver titanium dioxide coating supported by the material. The material may be a face mask adapted to be worn by a user. The coating may be applied via a Silver Titanium Dioxide solution. The solution may also be atomized for inhaling. Silver Titanium Dioxide acts as a photocatalyst at least due to the Titanium Dioxide to degrade organic molecules and microorganisms. The silver acts as a Bacteria stat, Fungus stat, and a Virus stat with or without light exposure. A titanium dioxide solution may be applied to skin. Exposure of the solution imbibed skin to light may be performed to remove or reduce tattoos.
PROBLEM TO BE SOLVED: To prepare a hair cosmetic, capable of imparting gloss, tensity and flexibility without any stickiness and good touch to hair by combining a specific alcohol with an acid and regulating the resultant composition so as to be used at a prescribed temperature. SOLUTION: This hair cosmetic comprises an aromatic alcohol and an acid and is used by heating at >=60 deg.C after application thereof to hair. Thereby, the aromatic alcohol and acid permeated into the hair produce an ester in the hair. Benzyl alcohol, phenethyl alcohol, phenoxyethanol, 2-benzyloxyethanol, etc., are preferred as the aromatic alcohol and the amount thereof blended is about 3-8wt.%. Glycolic acid, lactic acid, citric acid, malic acid, tartaric acid, etc., are preferred as the acid and the amount thereof blended is about 3-8wt.%. A hair rinse, a hair cream, a hair conditioner, etc., are cited as the hair cosmetic. The hair is preferably coated with the hair cosmetic, covered with an aluminum foil and heated by using a dryer when heating the hair cosmetic.
Patients and the caregivers accessing the full MORE program on the secured Website. The patients and caregivers will be instructed on how to complete the 1 week (or upon discharge) and 4 week surveys via REDCap or through the RC. This group has additional requirements in the 4-week survey to assess the helpfulness of the Stoma Care app.